Vol 7 Issue 11

Cell therapy bioprocessing and automation

Nov 2021

Expert Insight

Considerations for the development of autologous CAR-T cell products

Alexander Davidson,

Gerardo Santiago Toledo,

Kostadinka Lilova,

Michael Merges,

Peter Jones

11 January 2022

Expert Insight

Manufacturing of hematopoietic stem cell gene therapies: opportunities for process automation

Carlotta Peticone,

Emma Chan

20 December 2021

Expert Insight

Innovator Insight

Enabling clinical grade manufacturing of gene-engineered NK cells

Nina Möker,

Rizwan Romee,

Evelyn Ullrich

5 January 2022

Innovator Insight

Improving allogeneic manufacturing workflows

Dr. Evan Zynda,

Dr. Aditi Singh

4 November 2021

Innovator Insight

Interview

Lessons for advanced therapy manufacturing flexibility and productivity

James Miskin PhD

14 December 2021

Interview

Critical success factors for tomorrow’s cellular immunotherapies

Bernd Schmidt

13 December 2021

Interview

Expert Roundtable

A ddPCR primer: advantages, challenges, and key considerations when adopting Droplet Digital PCR for viral vector manufacture

Lauren M Drouin,

Fabien Dorange,

Bryan Silvey,

Mark White,

Steven Pincus

13 December 2021

Expert Roundtable

FastFacts

Making billions (of cells) with adherent cell cultures

Catherine Siler

6 December 2021

FastFacts

4D-Nucleofector<sup>®️</sup> LV Unit: Efficient, non-viral large-scale transfection for cell and gene therapy applications

4D-Nucleofector^®️ LV Unit: Efficient, non-viral large-scale transfection for cell and gene therapy applications

Timo Gleissner,

Andrea Toell

13 December 2021

FastFacts

Viewpoint

Driving CARs on the biomanufacturing road to clinical success

Chelsia Qiuxia Wang,

Andy Hee-Meng Tan

10 January 2022

Viewpoint

Translation and automation hurdles for cell therapies

Jenny A Prange,

Beatrix Rauch-Schmid

9 December 2021

Viewpoint

Innovation Insights November 2021

Expert Insight

No cell left behind: engineering gene therapies for cross correction

Jill M Weimer,

Jon J Brudvig

7 December 2021

Expert Insight

Interview

Engineering approaches to adopt automation in tissue engineered and cell therapy product manufacture

Ioannis Papantoniou

20 December 2021

Interview

Editorial

Adherent versus suspension based platforms: what is the near future of viral vector manufacturing?

Ramin Baghirzade

9 November 2021

Editorial

Innovator Insight

Optimizing downstream purification of high-quality plasmid DNA for gene therapy and vaccine production

Alejandro Becerra,

Johannes F Buyel

2 November 2021

Innovator Insight

Interview

Combating QC challenges and special needs of cell and gene therapy production

Félix Montero-Julian,

Rey Mali

23 November 2021

Interview

Stepping foot into a successful partnership to support your viral vector therapy through commercialization

Minh Hong,

Marc Gaal

12 January 2022

Interview

Finding a happy medium: meeting the rising demand for bioproduction media

Marlin Frechette

14 December 2021

Interview

Current trends in AAV downstream bioprocessing and future considerations

Michael Mercaldi

6 December 2021

Interview

mRNA: what is the best purification method?

Kelly Flook

2 December 2021

Poster

mRNA manufacturing platform using CIMmultus® and CIMac® technology for high recovery of stable mRNA drug substance with rapid HPLC analytics

Rok Sekirnik,

Tomas Kostelec

2 December 2021

FastFacts

FastFacts

Automate and close your cell therapy process with a flexible system: Sepax™ C-Pro capabilities

Sonia Bulsara

23 November 2021

FastFacts

How choosing the right transfection reagent can drastically bring down costs of AAV manufacturing

Maxime Dumont

23 November 2021

FastFacts

Automated cell expansion: Current technologies and trends

Gus Kilgore, PhD, Global Marketing Manager, Terumo BCT

Dalip Sethi, PhD, Director, Scientific Affairs, Terumo BCT

Kathie Schneider, Director, Global Commercial Lead, Terumo BCT

9 November 2021

Webinar

Watch now

Magnetic selection for consistent cellular starting material in autologous cell therapy manufacture

Kenneth Olsen, PhD, Senior R&D Scientist, Personalized Medicine Business Unit, Lonza

Rachel Perret, PhD, Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research

23 November 2021

Webinar

Watch now

Enabling clinical grade manufacturing of gene-engineered NK cells

Nina Möker, R&D Reagents Manager, Allogeneic Cell Therapy, Miltenyi Biotec

Prof. Dr. Evelyn Ullrich, Arbeitsgruppe Zelluläre Immunologie, Universitätsklinikum, Frankfurt am Main (kgu.de)

Rizwan Romee, MD, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute

Volker Huppert, Chief Development Officer Glycostem Therapeutics

30 November 2021

Webinar

Watch now

Developing stem cell therapies: expansion strategies and lessons learned

Shirley Mei, PhD, MSc, Investigator, OHRI

Lauralyn McIntyre, MD, MHSc, FRCPC, Senior Scientist, OHRI

Catherine Siler, PhD, Field Applications Scientist, Corning Life Sciences

8 December 2021

Webinar

Watch now

Putting the patient first: New modalities of manufacturing for cell therapy through real-time process changes

Chelsea C. White III, Schneider National Chair of Transportation & Logistics, H. Milton Stewart School of Industrial & Systems Engineering, Georgia Institute of Technology

Professor Ben Wang, Gwaltney Chair in Manufacturing Systems, Executive Director, Georgia Institute of Technology

Dr. Kan Wang, Senior Research Engineer, Georgia Tech Manufacturing Institute, Georgia Institute of Technology

9 December 2021

Webinar

Watch now

CELL & GENE THERAPY INSIGHTS

Dec 2021. Vol 7 Issue 11

FEATURING

Spotlight

Cell therapy bioprocessing and automation

Sponsors

Expert Insight

Considerations for the development of autologous CAR-T cell products

Manufacturing of hematopoietic stem cell gene therapies: opportunities for process automation

Innovator Insight

Enabling clinical grade manufacturing of gene-engineered NK cells

Improving allogeneic manufacturing workflows

Interview

Lessons for advanced therapy manufacturing flexibility and productivity

Critical success factors for tomorrow’s cellular immunotherapies

Expert Roundtable

A ddPCR primer: advantages, challenges, and key considerations when adopting Droplet Digital PCR for viral vector manufacture

FastFacts

Making billions (of cells) with adherent cell cultures

4D-Nucleofector®️ LV Unit: Efficient, non-viral large-scale transfection for cell and gene therapy applications

Viewpoint

Driving CARs on the biomanufacturing road to clinical success

Translation and automation hurdles for cell therapies

Report

Innovation Insights November 2021

Expert Insight

No cell left behind: engineering gene therapies for cross correction

Interview

Engineering approaches to adopt automation in tissue engineered and cell therapy product manufacture

Other articles

Editorial

Adherent versus suspension based platforms: what is the near future of viral vector manufacturing?

Innovator Insight

Optimizing downstream purification of high-quality plasmid DNA for gene therapy and vaccine production

Interview

Combating QC challenges and special needs of cell and gene therapy production

Stepping foot into a successful partnership to support your viral vector therapy through commercialization

Finding a happy medium: meeting the rising demand for bioproduction media

Current trends in AAV downstream bioprocessing and future considerations

mRNA: what is the best purification method?

mRNA manufacturing platform using CIMmultus® and CIMac® technology for high recovery of stable mRNA drug substance with rapid HPLC analytics

FastFacts

Automate and close your cell therapy process with a flexible system: Sepax™ C-Pro capabilities

How choosing the right transfection reagent can drastically bring down costs of AAV manufacturing

Webinars

Automated cell expansion: Current technologies and trends

Magnetic selection for consistent cellular starting material in autologous cell therapy manufacture

Enabling clinical grade manufacturing of gene-engineered NK cells

Developing stem cell therapies: expansion strategies and lessons learned

Putting the patient first: New modalities of manufacturing for cell therapy through real-time process changes

4D-Nucleofector^®️ LV Unit: Efficient, non-viral large-scale transfection for cell and gene therapy applications